 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| 12345678910111213...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Spontaneous resolution of foveoschisis secondary to intravitreal ranibizumab injection for myopic choroidal neovascularization (Pubmed Central) - Mar 9, 2025
No abstract available
- | Vabysmo (faricimab-svoa) / Roche
Journal, HEOR, Cost-effectiveness: Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia. (Pubmed Central) - Mar 7, 2025
Considering a willingness to pay threshold of $5988 per additional QALY, faricimab is a cost-effective alternative for both DME and nAMD for the Colombian healthcare system, showing dominance over other anti-vascular endothelial growth factor agents. Faricimab provides better health outcomes at lower costs vs other treatments.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Outcomes and comparative analysis of therapeutic approaches for choroidal neovascular membranes associated with optic nerve head drusen in pediatric patients. (Pubmed Central) - Mar 6, 2025
This study reinforces the equal efficacy of surgical, laser, and anti-VEGF treatments for CNVM associated with ONHD in pediatric patients. No adverse outcomes of anti-VEGF therapy were reported.
- ||| Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Journal, Adverse events: Increased Risk of Retinal Vasculitis May Be Associated with Aflibercept 8 mg: A Pharmacovigilance Analysis of the FAERS Database. (Pubmed Central) - Mar 6, 2025
This study identified a safety signal indicating a possible increased risk of retinal vasculitis with aflibercept 8?mg compared to the conventional 2?mg dose. This finding requires confirmation through future postmarketing studies.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Can changes on OCTA predict exudative activity on OCT in eyes with neovascular age related macular degeneration? The ACTOR Study. (Pubmed Central) - Mar 3, 2025
While OCTA may not be predictive of imminent exudative activity in nAMD, it brings additional information on MNV flow and holds potential as a tool for understanding vascular remodeling. Neovascularization remodeling and exudation may be two separate findings in the disease process in nAMD without necessarily having a causal relationship.
- Avastin (bevacizumab) / Roche
Observational data, Journal: Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs (Pubmed Central) - Feb 27, 2025
Dutch patients achieved higher VA after 60 months compared to the reference group. This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type.
- | Vabysmo (faricimab-svoa) / Roche, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. (Pubmed Central) - Feb 27, 2025
This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type. According to the injection frequency observed in clinical trials, aflibercept 8
- ||||||| Lytenava (bevacizumab-vikg) / Outlook Therap
Trial completion: NORSE EIGHT: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 26, 2025
P3, N=400, Completed, Sponsor: Outlook Therapeutics, Inc.
According to the injection frequency observed in clinical trials, aflibercept 8 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Journal, Monotherapy: CHARACTERISTICS OF 'NOTCH' IN RETINOPATHY OF PREMATURITY FOLLOWING INTRAVITREAL RANIBIZUMAB MONOTHERAPY. (Pubmed Central) - Feb 26, 2025
The reactivation rate after IVR was increased in ROP with notches. Notch may be a useful biomarker for reactivation after IVR in ROP.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Outcomes of Pro Re Nata versus Treat-and-Extend Anti-VEGF Injections for Myopic Macular Neovascularization in Multiethnic Patients in the United States. (Pubmed Central) - Feb 26, 2025
Because PRN provides favorable outcomes with fewer injections, it should be the first-line approach. However, a treat-and-extend approach with TES and TEM may be an option given individual patient factors.
- || Lucentis (ranibizumab) / Roche, Novartis
P2b data, Journal: Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type. (Pubmed Central) - Feb 25, 2025
Angiographic lesion characteristics were found to predict the response to sozinibercept combination therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: CHOROIDAL NEOVASCULARIZATION IN A CHILD WITH DOWN SYNDROME. (Pubmed Central) - Feb 25, 2025
CNV and associated macular degeneration may occur in Down syndrome with high myopia possibly because of the abnormal choroidal structure. In children with Down syndrome, regular fundus examinations with optical coherence tomography are important for early detection and treatment of CNV.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: The role of optical coherence tomography angiography in dome-shaped maculopathy. (Pubmed Central) - Feb 25, 2025
This diagnostic tool may be used to guide clinicians in their management of dome-shaped maculopathy, as demonstrated through the authors' experience. Optical coherence tomography angiography can also make it possible to visualize nonexudative CNVM lesions that may be missed on traditional imaging assessments.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Clinical characteristics and management outcomes of pediatric patients with Coats disease complicated with retinoschisis (retinal cyst). (Pubmed Central) - Feb 20, 2025
The presence of retinoschisis (retinal cyst) in Coats disease is strongly associated with retinal telangiectasia and exudation and is indicative of active vascular disease requiring effective ablative treatment. We propose a novel approach, endolaser photocoagulation combined with external drainage of cystic fluid and intravitreal ranibizumab injection, which was effective in achieving final anatomic improvement with retinal cyst resolution.
- |||| Vabysmo (faricimab-svoa) / Roche
Trial completion date, Trial primary completion date: POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Feb 18, 2025
P3, N=280, Recruiting, Sponsor: Hoffmann-La Roche
We propose a novel approach, endolaser photocoagulation combined with external drainage of cystic fluid and intravitreal ranibizumab injection, which was effective in achieving final anatomic improvement with retinal cyst resolution. Trial completion date: Nov 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Aug 2025
- | Lucentis (ranibizumab) / Roche, Novartis, nintedanib / Generic mfg.
Preclinical, Journal: Nintedanib and Ranibizumab Attenuates Pathological Neovascularization in a Rat Model of Oxygen Induced Retinopathy. (Pubmed Central) - Feb 15, 2025
Trial completion date: Nov 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Aug 2025 No abstract available
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Aflibercept to treat retinopathy of prematurity: need for more research. (Pubmed Central) - Feb 13, 2025
We summarize the clinical trial results and provide a side-by-side comparisons of the three drugs. Despite FDA approval of the use of aflibercept to treat ROP, there is a need for more research as the body of knowledge regarding this agent to treat ROP is limited.
- | Lusefi (luseogliflozin) / Taisho, Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial. (Pubmed Central) - Feb 12, 2025
Although the overall number of anti-VEGF injections in the target eye showed no significant difference, some patients responded favourably to SGLT2i and required fewer injections. The reduction in fellow eye injections suggests SGLT2i's efficacy in treating early-stage DMO.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: The Impact of Glycemic Control on Ranibizumab Efficacy in Diabetic Retinopathy: A Retrospective Analysis. (Pubmed Central) - Feb 10, 2025
The reduction in fellow eye injections suggests SGLT2i's efficacy in treating early-stage DMO. Our study indicates that HbA1c control influences the treatment outcomes of intravitreal Ranibizumab for DME, with better responses observed in patients whose HbA1c is below 7%.
- |||||| Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date: Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (clinicaltrials.gov) - Feb 8, 2025
P3, N=634, Recruiting, Sponsor: Hoffmann-La Roche
Our study indicates that HbA1c control influences the treatment outcomes of intravitreal Ranibizumab for DME, with better responses observed in patients whose HbA1c is below 7%. Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2022 --> Nov 2026
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Regulatory PMS Study for Lucentis (clinicaltrials.gov) - Feb 7, 2025
P=N/A, N=71, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2022 --> Nov 2026 Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment. (Pubmed Central) - Feb 5, 2025
Ranibizumab treatment reduced the intraocular but not circulating activation of classical and alternative complement pathways in RVO patients. Differences in intraocular complement proteins were observed between BRVO and CRVO patients, which may reflect different pathogenesis.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes After Intravitreal Anti-Vascular Endothelial Growth Factors Injection. (Pubmed Central) - Feb 4, 2025
A similar increase in IOP was observed in eyes with low and intermediate volumes, but the increase was less pronounced in those with high volumes after the IVI. Prefilled syringe form showed a lower IOP increase tendency in comparison with vial-prepared forms of the molecules.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR, Real-world evidence: Real-world evidence of anti-VEGF therapies in patients with neovascular age-related macular degeneration in Italy: The RADIANCE study. (Pubmed Central) - Feb 4, 2025
Prefilled syringe form showed a lower IOP increase tendency in comparison with vial-prepared forms of the molecules. The results of the RADIANCE study suggest an overall moderate effectiveness after 1 year of treatment with anti-VEGF in na
- ||||| surabgene lomparvovec (ABBV-RGX-314) / REGENXBIO, AbbVie
Enrollment change: ATMOSPHERE: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (clinicaltrials.gov) - Jan 29, 2025
P2/3, N=540, Recruiting, Sponsor: AbbVie
The results of the RADIANCE study suggest an overall moderate effectiveness after 1 year of treatment with anti-VEGF in na N=300 --> 540
- || Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date: PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov) - Jan 17, 2025
P3, N=174, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=300 --> 540 Trial completion date: May 2024 --> Jun 2025
- | Vabysmo (faricimab-svoa) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: FAR-WEST: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (clinicaltrials.gov) - Jan 16, 2025
P=N/A, N=100, Recruiting, Sponsor: Nantes University Hospital
Trial completion date: May 2024 --> Jun 2025 Not yet recruiting --> Recruiting
- | Journal: Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. (Pubmed Central) - Jan 15, 2025
Not yet recruiting --> Recruiting Faricimab may be more protective than other anti-VEGF injections against SMH in patients with neovascular age-related macular degeneration.
- ||| vamikibart (RG6179) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P1 trial, Monotherapy: DOVETAIL: A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema (clinicaltrials.gov) - Jan 13, 2025
P1, N=85, Completed, Sponsor: Hoffmann-La Roche
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: NR2E3-Associated Retinopathy Presenting with Bilateral Choroidal Neovascularization. (Pubmed Central) - Jan 12, 2025
We describe a case of bilateral CNV in a young patient with enhanced S-cone syndrome, discuss differentials and treatment approaches. This case highlights the risk of CNV in ESCS and the importance of family screening and follow-up in affected relatives.
- | Journal: Drugs for age-related macular degeneration. (Pubmed Central) - Jan 12, 2025
This case highlights the risk of CNV in ESCS and the importance of family screening and follow-up in affected relatives. No abstract available
- | Vabysmo (faricimab-svoa) / Roche
Journal, Real-world evidence, Real-world: Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab. (Pubmed Central) - Jan 6, 2025
At 12 months, nAMD patients with previous record of high treatment burden when switched to faricimab maintained VAs and improved anatomic outcomes on extended treatment intervals. Physician bias is inherent in these types of observational studies so a prospective, randomized, controlled trial is recommended to validate these findings.
- | Journal: Immediate response to intravitreal treatment for macular edema due to diabetes and retinal vein occlusion. (Pubmed Central) - Jan 3, 2025
Maximum reduction in central retinal thickness was seen following triamcinolone acetonide injection. Cystoid edema showed better immediate response than spongy retinal thickening.
- || Vabysmo (faricimab-svoa) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Review, Journal: Indirect comparison of anti-angiogenic agents in the treatment of diabetic macular edema (Pubmed Central) - Dec 28, 2024
Cystoid edema showed better immediate response than spongy retinal thickening. The clinical efficacy and safety of faricimab, aflibercept and ranibizumab are comparable in adult patients with DME with a fewer number of faricimab IVIs vs comparators.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series. (Pubmed Central) - Dec 26, 2024
The clinical efficacy and safety of faricimab, aflibercept and ranibizumab are comparable in adult patients with DME with a fewer number of faricimab IVIs vs comparators. Infants of A-ROP treated with IVR have a higher incidence and earlier reactivation, while those treated with IVB have less incidence and delayed reactivation, albeit with a higher possibility of regression with a PAR.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: The Association of Primary Open Angle Glaucoma and Ocular Hypertension with Anti-VEGF Injections. (Pubmed Central) - Dec 24, 2024
Compared to age-matched controls, patients treated with anti-VEGF agents demonstrated an increased rate of OHT, SE-IOP, and POAG which correlated with the number of IVIs. However, additional prospective studies are needed to determine if there is a true association between intravitreal anti-VEGF injections and glaucoma.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Strategic delivery of rapamycin and ranibizumab with intravitreal hydrogel depot disrupts multipathway-driven angiogenesis loop for boosted wAMD therapy. (Pubmed Central) - Dec 21, 2024
Notably, the sequential administration of ranibizumab and Rab&Rapa-M@G further enhances the overall anti-wAMD efficacy, achieved through sequential delivery of Rab and Rapa, allowing for a more precise grasp of the treatment window. In conclusion, this hydrogel depot design, with its sequential and sustained delivery of mTOR inhibitors and anti-VEGF antibodies, offers a promising strategy for multi-target synergistic therapy in wAMD.
- ||| Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal, Adverse events: Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: a World Health Organization pharmacovigilance study. (Pubmed Central) - Dec 21, 2024
In this pharmacovigilance case-noncase study, there was significantly increased reporting of cardiovascular and cerebrovascular ADRs after intravitreal anti-VEGF treatment. Although ranibizumab may exhibit superior systemic safety regarding its biological characteristics, it is crucial not to overlook the occurrence of cardiovascular and cerebrovascular ADRs considering its higher reporting rate than bevacizumab or aflibercept.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial. (Pubmed Central) - Dec 19, 2024
P2/3
Results of this randomized clinical trial suggest that TPA may increase the chance of visual acuity gain when added to ranibizumab therapy for neovascular AMD in eyes with SMH, warranting consideration of additional clinical trials. ClinicalTrials.gov Identifier: NCT01835067.
- || Clinical, Journal: Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections. (Pubmed Central) - Dec 18, 2024
Topical fixed combination anti-glaucoma medication used as a prophylactic treatment before intravitreal anti-VEGF injections significantly prevented IOP spikes post-injection, with a comparable effect among three medications. Prophylactic treatment of IOP spikes should be considered as standard care to prevent further damage in patients with compromised retinal vascular and optic nerve perfusion.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Retinotopic cortical mapping in objective functional monitoring of macular therapy. (Pubmed Central) - Dec 17, 2024
The data show that retinotopic mapping using fMRI can successfully be applied objectively to evaluate the therapeutic response in nAMD patients treated with anti-vascular endothelial growth factor therapy. This demonstrates the ability of retinotopic mapping to provide an objective assessment of functional recovery at a cortical level; the technique can therefore be applied, in other degenerative macular diseases, to the assessment of potential therapeutic interventions such as gene therapy or cell replacement therapy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Correlation of Functional and Structural Outcomes with Serum Antibody Profiles in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial. (Pubmed Central) - Dec 17, 2024
Up- and downregulations of antibodies were observed over the course of treatment with ranibizumab. Some antibodies seemed to have a fair correlation with the classification of initial and deferred responders.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema. (Pubmed Central) - Dec 16, 2024
P3
Some antibodies seemed to have a fair correlation with the classification of initial and deferred responders. In this exploratory post hoc analysis of data from the RIDE/RISE (NCT00473382/NCT00473330) clinical trials of ranibizumab for DME, the NEI
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Evaluation of Sustained Intraocular Pressure Elevations Across Antivascular Endothelial Growth Factor Agents. (Pubmed Central) - Dec 16, 2024
Although not all anti-VEGF agents are associated with IOP-related adverse effects, bevacizumab carries an increased risk for sustained IOP elevation. Further investigation into the long-term effects of bevacizumab on IOP and glaucoma and a comparison with other anti-VEGF agents may be warranted.
- | Vabysmo (faricimab-svoa) / Roche
Journal: Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison. (Pubmed Central) - Dec 16, 2024
Further investigation into the long-term effects of bevacizumab on IOP and glaucoma and a comparison with other anti-VEGF agents may be warranted. To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept, bevacizumab, and ranibizumab, in patients with neovascular age-related macular degeneration (nAMD) na
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Comparison of visual acuity outcome and choroidal thickness variation of intravitreal ranibizumab injection for myopic choroidal neovascularization with or without dome-shaped macula. (Pubmed Central) - Dec 13, 2024
The visual acuity significantly improved at 1 month after ranibizumab injection and it was recovery sooner in extrafoveal choroidal neovascularization (CNV) group than in subfoveal CNV group. The CT was thinner in eyes with DSM, which was significantly correlated with AL.
- || Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Edridge Green Lecture 2022-demystifying clinical trials and regulatory approvals in drug development. (Pubmed Central) - Dec 6, 2024
Approvals for key retinal drugs, such as ranibizumab and aflibercept, treatments for AMD and diabetic macular oedema, are discussed highlighting criteria like the 15-letter gain/loss in visual acuity as approvable/clinical meaningful efficacy endpoints...In particular, it is important to understand the reasons behind selection of trial design, inclusion and exclusion criteria, primary and secondary efficacy endpoints and safety endpoints. Since this lecture, there have been important changes in this field including new guidance from the Food and Drug Administration (FDA) as well as lessons learnt from recent drug approvals that are included in this manuscript.
- | levosulpiride / Generic mfg.
Trial completion date, Trial primary completion date: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - Dec 6, 2024
P2, N=120, Recruiting, Sponsor: Carmen Clapp
Since this lecture, there have been important changes in this field including new guidance from the Food and Drug Administration (FDA) as well as lessons learnt from recent drug approvals that are included in this manuscript. Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
- | Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Effects on corneal endothelium of intravitreal injection of anti-VEGF drugs. (Pubmed Central) - Dec 2, 2024
No statistically significant data emerged from the analyses (p-value is >0.05). The study demonstrated a statistically significant reduction of corneal endothelial cells in patients undergoing intravitreal injection treatment per number of injections with anti-VEGF, this reduction being independent of the type of anti-VEGF used (Bevacizumab, Ranibizumab, Aflibercept and Brolucizumab).
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial-24-week Outcomes of Uveitic Macular Edema Retreatment. (Pubmed Central) - Nov 30, 2024
The study demonstrated a statistically significant reduction of corneal endothelial cells in patients undergoing intravitreal injection treatment per number of injections with anti-VEGF, this reduction being independent of the type of anti-VEGF used (Bevacizumab, Ranibizumab, Aflibercept and Brolucizumab). Dexamethasone was more effective that methotrexate and ranibizumab for the treatment of persistent or recurrent uveitic macular edema through 24 weeks, with manageable side effects.